natgillin/translations-raw huggingface dataset:
Treatment should be temporarily interrupted if gastrointestinal adverse reactions are observed until these adverse reactions resolve. 
Če pride do gastrointestinalnih neželenih učinkov, je treba zdravljenje začasno prekiniti, dokler ti neželeni učinki ne izzvenijo.
Patients and their caregivers must be instructed on important administration instructions for Rivastigmine 3M Health Care Ltd. transdermal patch (see section 4.2). 
Bolnike in njihove negovalce je treba opozoriti na pomembne napotke za uporabo transdermalnega obliža Rivastigmin 3M Health Care Ltd. (glejte poglavje 4.2).
The dose of rivastigmine released from the transdermal patch over 24 hours (mg/24 h) cannot be directly equated to the amount (mg) of rivastigmine contained in a capsule with respect to plasma concentration produced over 24 hours. 
Glede koncentracij, ki jih rivastigmin dosega v plazmi v obdobju 24 ur, odmerka rivastigmina, ki se v 24 urah sprosti iz transdermalnega obliža (v mg/24 h), ni mogoče neposredno enačiti s količino rivastigmina (v mg), ki jo vsebuje kapsula.
Uncommon (may affect up to 1 in 100 people) - Problems with your heartbeat such as slow heartbeat - Seeing things that are not really there (hallucinations) - Stomach ulcer - Dehydration (losing too much fluid) - Hyperactivity (high level of activity, restlessness) - Aggression 
Občasni (pojavijo se lahko pri največ 1 od 100 bolnikov) - motnje srčnega ritma, kot je prepočasen srčni utrip - vidna zaznava nečesa, česar v resnici ni tam (halucinacije) - želodčna razjeda - dehidracija (čezmerna izguba tekočine) - hiperaktivnost (povečana stopnja aktivnosti, nemir) - agresivnost
- if you have a skin reaction spreading beyond the patch size, if there is a more intense local reaction (such as blisters, increasing skin inflammation, swelling) and if it does not improve within 48 hours after removal of the transdermal patch. 
- če opazite kožno reakcijo, ki se širi preko površine, ki jo pokriva transdermalni obliž, če je reakcija na tem mestu močneje izražena (če se pojavijo mehurčki, če je vnetje oziroma oteklina vse bolj izrazita) in če se ti znaki v 48 urah po odstranitvi transdermalnega obliža ne izboljšajo.
When and for how long to apply your Rivastigmine 3M Health Care Ltd. transdermal patch - To benefit from treatment, you must apply a new patch every day, preferably at the same time of day. 
Kdaj namestiti transdermalni obliž Rivastigmin 3M Health Care Ltd. in za koliko časa - Da bi vam zdravljenje koristilo, morate obliž zamenjati vsak dan, če se le da vsak dan ob istem
This may indicate a potential for rivastigmine transdermal patches to induce mild erythema in patients. 
To lahko nakazuje možnost, da bi transdermalni obliži z rivastigminom sprožili nastanek blage rdečine pri bolnikih.
rivastigmine, renal elimination was rapid and essentially complete (>90%) within 24 hours. 
Po zaužitju rivastigmina, označenega s 14C, je bilo ledvično izločanje hitro, saj se je dejansko ves (>90%) izločil v 24 urah.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS POUCH 
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
Special populations - Paediatric population: There is no relevant use of Rivastigmine 3M Health Care Ltd. in the paediatric population in the treatment of Alzheimer's disease. 
- Pediatrična populacija: Zdravila Rivastigmin 3M Health Care Ltd. ni smiselno uporabljati za zdravljenje Alzheimerjeve bolezni pri pediatrični populaciji.
Rectangular patches, approximately 3.5 cm by 2.6 cm with rounded corners. 
Pravokotni, približno 3,5 cm krat 2,6 cm veliki obliži z zaobljenimi vogali.
SPECIAL STORAGE CONDITIONS Store in the original package in order to protect from light. 
POSEBNA NAVODILA ZA SHRANJEVANJE Shranjujte v originalni ovojnini za zagotovitev zaščite pred svetlobo.
The metabolite-to-parent AUC∞ ratio was around 0.7 after transdermal patch administration versus 3.5 after oral administration, indicating that much less metabolism occurred after dermal compared to oral treatment. 
Razmerje med AUC∞ presnovka in izhodne učinkovine je bilo približno 0,7 po namestitvi transdermalnega obliža v primerjavi s 3,5 po peroralni aplikaciji zdravila, kar nakazuje, da je bil metabolizem precej manj obsežen po dermalnem zdravljenju v primerjavi s peroralnim.
Where to apply your Rivastigmine 3M Health Care Ltd. transdermal patch - Before you apply a patch, make sure that your skin is clean, dry and hairless, free of any powder, oil, moisturiser or lotion that could keep the patch from sticking to your skin properly, free of cuts, rashes and/or irritations. 
Kam namestiti transdermalni obliž Rivastigmin 3M Health Care Ltd. - Preden namestite obliž, se prepričajte, da je izbrani predel kože čist, suh in neporaščen, da na izbranem predelu kože ni pudra, olja, vlažilne kreme ali losjona, ki bi lahko preprečili, da se obliž pravilno prilepi na kožo, in da na izbranem predelu kože ni ureznin, izpuščajev ter da
In view of its pharmacodynamic effects, rivastigmine should not be given concomitantly with other cholinomimetic substances and might interfere with the activity of anticholinergic medicinal products. 
Zaradi njegovih farmakodinamičnih učinkov se rivastigmina ne sme uporabljati skupaj z drugimi holinomimetičnimi snovmi.
Rare (may affect up to 1 in 1,000 people) - Falling 
Redki (pojavijo se lahko pri največ 1 od 1.000 bolnikov) - padci
After oral administration, Cmax and AUC of rivastigmine were more than twice as high in Alzheimer patients with moderate renal impairment compared with healthy subjects; however there were no changes in Cmax and AUC of rivastigmine in Alzheimer patients with severe renal impairment. 
Po peroralnem odmerjanju sta bili Cmax in AUC pri bolnikih z Alzheimerjevo demenco in z zmerno ledvično okvaro rivastigmina več kot dvakrat večji kot pri zdravih osebah, pri osebah z Alzheimerjevo demenco in s težko ledvično okvaro pa ni bilo sprememb Cmax in AUC rivastigmina.
Rivastigmine 3M Health Care Ltd. transdermal patches may cause fainting or severe confusion. 
Transdermalni obliži Rivastigmin 3M Health Care Ltd. lahko povzročajo omedlevico ali hudo zmedenost.
ADCS-CGIC scores <4 indicate improvement. 
<4 na lestvici ADCS-CGIC pomeni izboljšanje.
However, due to increased exposure in these populations as observed with the oral forms, dosing recommendations to titrate according to individual tolerability should be closely followed as patients with clinically significant renal impairment might experience more adverse reactions (see sections 4.4 and 5.2). 
Vendar se je treba zaradi povečane izpostavljenosti zdravilu pri teh populacijah, kar so opažali pri uporabi peroralnih oblik zdravila, natančno ravnati po priporočilih, naj se odmerjanje titrira glede na individualno prenašanje, saj je pri bolnikih s klinično pomembno okvaro ledvic lahko število neželenih učinkov večje (glejte poglavji 4.4 in 5.2).
Patients and caregivers should be instructed on important administration instructions: - The previous day's patch must be removed before applying a new one every day (see section 4.9). 
Bolnike in negovalce je treba opozoriti na pomembne napotke za uporabo zdravila: - Vsak dan je treba pred nameščanjem novega obliža odstraniti obliž predhodnega dne (glejte
There have been rare post-marketing reports of patients experiencing disseminated skin hypersensitivity reactions when administered rivastigmine irrespective of the route of administration (oral, transdermal). 
V redkih poročilih iz obdobja po prihodu zdravila na trg so opisovali bolnike, pri katerih je pri aplikaciji rivastigmina prišlo do diseminirane kožne preobčutljivostne reakcije ne glede na način vnosa zdravila (peroralno ali transdermalno).
Special populations: - Patients with body weight below 50 kg may experience more adverse reactions and may be more likely to discontinue due to adverse reactions (see section 4.2). 
Posebne skupine bolnikov: - Pri bolnikih s telesno maso manjšo od 50 kg je lahko število neželenih učinkov večje, obstaja pa tudi večja verjetnost, da bodo zaradi neželenih učinkov zdravljenje prekinili (glejte poglavje 4.2).
Rivastigmine 9.5 mg/24 h N = 271 
Rivastigmin 9,5 mg/24 h N = 271
The following adverse reactions have only been observed with rivastigmine capsules and oral solution and not in clinical studies with rivastigmine transdermal patches: somnolence, malaise, tremor, confusion, sweating increased (common); duodenal ulcers, angina pectoris (rare); gastrointestinal haemorrhage (very rare); and some cases of severe vomiting were associated with oesophageal rupture (not known). 
Naslednje neželene učinke so opažali samo pri uporabi kapsul in peroralne raztopine z rivastigminom, ne pa v kliničnih študijah s transdermalnimi obliži z rivastigminom: somnolenco, splošno slabo počutje, tremor, zmedenost, povečano potenje (pogosto); razjede dvanajstnika, angino pektoris (redko); krvavitev v prebavila (zelo redko); in nekaj primerov hudega bruhanja, ki je bilo povezano z rupturo
Based on evidence from in vitro and animal studies, the major cytochrome P450 isoenzymes are minimally involved in rivastigmine metabolism. 
Raziskave in vitro in raziskave na živalih dokazujejo, da pri presnovi rivastigmina le v zelo majhni meri sodelujejo glavni izoencimi s citokromom P450.
LIST OF EXCIPIENTS Also contains polyester, ethyl vinyl acetate, acrylate copolymer adhesive and isopropyl myristate. 
Vsebuje tudi: poliester, etilvinilacetat, adhezivni akrilatni kopolimer in izopropilmiristat.
What Rivastigmine 3M Health Care Ltd. is and what it is used for 
Kaj je zdravilo Rivastigmin 3M Health Care Ltd. in za kaj ga uporabljamo
Each patch consists of a combination of a removable, transparent, split release liner, a functional layer containing drug-inadhesive (DIA) matrix, and a protective backing layer. 
En obliž je sestavljen iz odstranljive, prozorne opne, iz funkcijske plasti, ki vsebuje matriks ''zdravilo-v-adhezivu'' (DIA - drugin-adhesive), in iz zaščitne krovne plasti.
ITT: Intent-To-Treat; LOCF: Last Observation Carried Forward 1 Based on ANCOVA with treatment and country as factors and baseline value as a covariate. 
1 Na podlagi ANCOVA z zdravljenjem in državo kot faktorjema in izhodiščno vrednostjo kot sospremenljivko.
As suggested by compartmental modelling, 9.5 mg/24 h transdermal patches exhibited exposure similar to that provided by an oral dose of 12 mg/day. 
Kot nakazuje modeliranje kompartmentov, je izpostavljenost zdravilu iz transdermalnega obliža 9,5 mg/24 h podobna kot pri peroralnem odmerku približno 12 mg/dan.
Used transdermal patches should be folded in half, with the adhesive side inwards, placed in the original pouch and discarded safely and out of the sight and reach of children. 
Po uporabi transdermalni obliž prepognite na pol z lepljivo stranjo navznoter, vložite v originalno vrečko in varno zavrzite nedosegljivo otrokom.
Every 24 hours take off the previous patch before putting ONE new patch on to ONLY ONE of the following possible locations. 
Vsakih 24 ur najprej odstranite prešnji obliž, nato pa namestite EN nov obliž na SAMO ENO od naslednjih
• Do not cut the patch into pieces. 
• Obliža ne smete rezati na manjše dele.
If well tolerated and only after a minimum of six months of treatment at 9.5 mg/24 h, the treating physician may consider increasing the dose to 13.3 mg/24 h in patients who have demonstrated a meaningful cognitive deterioration (e.g. decrease in the MMSE) and/or functional decline (based on physician judgement) while on the recommended daily effective dose of 9.5 mg/24 h (see section 5.1). 
Če bolnik ta odmerek dobro prenaša, lahko po najmanj šestih mesecih zdravljenja z odmerkom 9,5 mg/24 h lečeči zdravnik razmisli o zvišanju odmerka na 13,3 mg/24 h, in sicer pri bolnikih, pri katerih kaže, da je med zdravljenjem s priporočenim dnevnim učinkovitim odmerkom 9,5 mg/24 h prišlo do pomembnega kognitivnega poslabšanja (na primer do poslabšanja rezultata MMSE) in/ali funkcionalnega upada (po zdravnikovi presoji) (glejte poglavje 5.1).
Therefore, in patients with dementia treated with rivastigmine, the ability to continue driving or operating complex machines should be routinely evaluated by the treating physician. 
Zato mora lečeči zdravnik pri bolnikih z demenco, ki jemljejo rivastigmin, redno ocenjevati sposobnost za upravljanje motornih vozil ali zapletenih strojev.
Each transdermal patch of 8.3 cm2 contains 14.33 mg of rivastigmine. 
En transdermalni obliž velikosti 8,3 cm2 vsebuje 14,33 mg rivastigmina.
- If the patch falls off, a new one should be applied for the rest of the day, then it should be replaced at the same time as usual the next day. 
- Če se obliž odlepi, je treba namestiti nov obliž za preostanek tega dne, nato pa novi obliž naslednji dan zamenjati ob istem času kot običajno.
Each patch is sealed in a pouch that protects it until you are ready to put it on. Do not open the pouch or remove a patch until just before you apply it. 
Vsak obliž je zaprt v vrečki, ki ga ščiti, dokler ga ne želite namestiti.
Each transdermal patch of 4.15 cm2 contains 7.17 mg of rivastigmine. 
En transdermalni obliž velikosti 4,15 cm2 vsebuje 7,17 mg rivastigmina.
At steady state, trough levels are approximately 50% of peak levels, in contrast to oral administration, with which concentrations fall off to virtually zero between doses. 
V stanju dinamičnega ravnovesja je spodnja meja fluktuacije koncentracije približno 50% vrednosti zgornje meje, v nasprotju s peroralnim odmerjanjem, pri katerem se koncentracije med odmerjanji znižajo praktično na nič.
However, use of rivastigmine patch may lead to allergic contact dermatitis. 
Te reakcije same po sebi še ne kažejo na senzitizacijo, vendar lahko uporaba rivastigmina v transdermalnem obližu povzroči alergijski kontaktni dermatitis.
Efficacy was established by the use of ADAS-Cog (Alzheimer's Disease Assessment Scale - Cognitive subscale, a performance-based measure of cognition) and the ADCS-IADL (Alzheimer's Disease Cooperative Study - Instrumental Activities of Daily Living) assessing instrumental activities which include maintaining finances, meal preparation, shopping, ability to orient oneself to surroundings, ability to be left unattended. 
Učinkovitost so ugotavljali z metodama ADAS-Cog (Alzheimer's Disease Assessment Scale - Cognitive subscale, Lestvica za oceno kognitivnih sposobnosti bolnikov z Alzheimerjevo boleznijo, merilo kognitivne zmogljivosti, ki temelji na izvrševanju aktivnosti) in ADCS-IADL (Alzheimer's Disease Cooperative StudyInstrumental Activities of Daily Living, ocena zahtevnejših vsakodnevnih aktivnosti), s katero je mogoče oceniti bolnikove sposobnosti izvajanja aktivnosti, med katere sodijo ukvarjanje z denarnimi zadevami, pripravljanje obrokov, nakupovanje, zmožnosti orientacije v okolju in samostojnost do te mere, da je bolnika mogoče pustiti brez nadzora.
Carefully titrate and monitor these patients for adverse reactions (e.g. excessive nausea or vomiting) and consider reducing the maintenance dose to the 4.6 mg/24 h transdermal patch if such adverse reactions develop. 
Tem bolnikom je treba odmerek titrirati previdno in jih skrbno spremljati glede neželenih učinkov (na primer pretirane navzee ali bruhanja) ter v primeru, da pride do teh neželenih učinkov, razmisliti o znižanju vzdrževalnega odmerka na 4,6 mg/24 h.
However, these events did not occur at a higher frequency with rivastigmine 13.3 mg/24 h transdermal patches than with placebo. 
Vendar pa se ti dogodki niso pojavljali pogosteje pri uporabi transdermalnega obliža z rivastigminom 13,3 mg/24 h v
Manufacturer Enestia 
Izdelovalec Enestia
After oral administration, the Cmax of rivastigmine was approximately 60% higher and the AUC of rivastigmine was more than twice as high in subjects with mild to moderate hepatic impairment than in healthy subjects. 
Po peroralnem odmerjanju je bila Cmax rivastigmina za približno 60 % večja in AUC rivastigmina več kot dvakrat večja pri osebah z blago do zmerno jetrno okvaro kot pri zdravih osebah.
The fluctuation index (FI), a measure of the relative difference between peak and trough concentrations ((Cmax-Cmin)/Cavg), was 0.58 for rivastigmine 4.6 mg/24 h transdermal patches, 0.77 for rivastigmine 9.5 mg/24 h transdermal patches and 0.72 for rivastigmine 13.3 mg/24 h transdermal patches, thus demonstrating a much smaller fluctuation between trough and peak concentrations than for the oral formulation (FI = 3.96 (6 mg/day) and 4.15 (12 mg/day)). 
Fluktuacijski indeks(FI), ki izraža relativno razliko med najvišjimi in najnižjimi koncentracijami ((Cmax-Cmin)/Cavg; pri tem je Cavg povprečna koncentracija v obdobju odmerjanja), je bil 0,58 pri transdermalnih obližih z rivastigminom 4,6 mg/24 h, 0,77 pri transdermalnih obližih z rivastigminom 9,5 mg/24 h in 0,72 pri transdermalnih obližih z rivastigminom 13,3 mg/24 h, kar kaže na veliko manjšo fluktuacijo od najnižjih do najvišjih koncentracij kot pri peroralnem odmerjanju (FI = 3,96 za odmerjanje 6 mg/dan in 4,15 za odmerjanje
The most commonly observed severe symptoms with rivastigmine 9.5 mg/24 h transdermal patches were pruritus (1.7%) and erythema (1.1%). 
Najpogosteje opažena huda simptoma s transdermalnimi obliži z rivastigminom 9,5 mg/24 h sta bila srbenje (1,7%) in rdečina (1,1%).
Reapplication to the exact same skin location within 14 days should be avoided to minimise the potential risk of skin irritation. 
Da bi kar najbolj zmanjšali možnost draženja kože, se transdermalnega obliža ne sme ponovno namestiti na isti predel kože v roku 14 dni.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each transdermal patch releases 4.6 mg of rivastigmine per 24 hours. 
KAKOVOSTNA IN KOLIČINSKA SESTAVA En transdermalni obliž sprosti 4,6 mg rivastigmina na 24 ur.
Switching from capsules or oral solution to transdermal patches Based on comparable exposure between oral and transdermal rivastigmine (see section 5.2), patients treated with rivastigmine capsules or oral solution can be switched to Rivastigmine 3M Health Care Ltd. transdermal patches as follows: - A patient on a dose of 3 mg/day oral rivastigmine can be switched to 4.6 mg/24 h transdermal patches. 
Prehod z zdravljenja s kapsulami ali peroralno raztopino na zdravljenje z obliži Glede na to, da je izpostavljenost rivastigminu primerljiva pri peroralni in transdermalni aplikaciji (glejte poglavje 5.2), lahko bolniki, ki se zdravijo s kapsulami ali peroralno raztopino rivastigmina, preidejo na zdravljenje s transdermalnimi obliži Rivastigmin 3M Health Care Ltd. na naslednji način: - Bolnik, ki jemlje rivastigmin peroralno v odmerku 3 mg/dan, lahko preide na zdravljenje s
What you need to know before you use Rivastigmine 3M Health Care Ltd. 
Kaj morate vedeti, preden boste uporabili zdravilo Rivastigmin 3M Health Care Ltd.
After switching to 4.6 mg/24 h transdermal patches, provided these are well tolerated after a minimum of four weeks of treatment, the dose of 4.6 mg/24 h should be increased to 9.5 mg/24 h, which is the recommended effective dose. 
Če bolnik po prehodu na zdravljenje s transdermalnimi obliži 4,6 mg/24 h ta odmerek dobro prenaša, je treba po najmanj štirih tednih zvišati odmerek s 4,6 mg/24 h na 9,5 mg/24 h, kar je priporočeni učinkoviti
QUALITATIVE AND QUANTITATIVE COMPOSITION Each transdermal patch releases 9.5 mg of rivastigmine per 24 hours. 
KAKOVOSTNA IN KOLIČINSKA SESTAVA En transdermalni obliž sprosti 9,5 mg rivastigmina na 24 ur.
These include the ADAS-Cog (Alzheimer's Disease Assessment Scale - Cognitive subscale, a performance-based measure of cognition) and the ADCS-CGIC (Alzheimer's Disease Cooperative Study - Clinician's Global Impression of Change, a comprehensive global assessment of the patient by the physician incorporating caregiver input), and the ADCS-ADL (Alzheimer's Disease Cooperative StudyActivities of Daily Living, a caregiver-rated assessment of the activities of daily living including personal hygiene, feeding, dressing, household chores such as shopping, retention of ability to orient oneself to surroundings as well as involvement in activities related to finances). 
Med njimi so ADAS-Cog (Alzheimer's Disease Assessment Scale - Cognitive subscale, Lestvica za oceno kognitivnih sposobnosti bolnikov z Alzheimerjevo boleznijo, merilo kognitivne zmogljivosti, ki temelji na izvrševanju aktivnosti), ADCS-CGIC (Alzheimer's Disease Cooperative Study - Clinician's Global Impression of Change, Zdravnikova ocena spremembe bolezni po Kooperativni študiji Alzheimerjeve bolezni, vsestranska globalna ocena bolnika, ki jo poda zdravnik ob upoštevanju negovalčeve ocene) in ADCS-ADL (Alzheimer's Disease Cooperative Study - Activities of Daily Living, ocena vsakodnevnih aktivnosti po Kooperativni študiji Alzheimerjeve bolezni, negovalčeva ocena vsakodnevnih aktivnosti, med drugim osebne higiene, hranjenja, oblačenja, gospodinjskih opravil, na primer nakupovanja, ohranjanja zmožnosti orientacije v okolju kot tudi ukvarjanja z denarnimi zadevami).
If you are pregnant, the benefits of using Rivastigmine 3M Health Care Ltd. transdermal patches must be assessed against the possible effects on your unborn child. Rivastigmine 3M Health Care Ltd. should not be used during pregnancy unless clearly necessary. 
V primeru, da ste noseči, je treba pretehtati koristi uporabe zdravila Rivastigmin 3M Health Care Ltd. in možne učinke na nerojenega otroka.
Each transdermal patch consists of three layers; a backing layer, an adhesive layer containing the medicine and a transparent, split release liner. 
En obliž je sestavljen iz treh plasti; krovne plasti, adhezivne plasti, ki vsebuje zdravilo, in prozorne zaščitne plasti, ki se jo odstrani.
Less than 1% of the administered dose is excreted in the faeces. 
Manj kot 1 % apliciranega
Patients involved in the active comparator controlled study had an initial baseline MMSE score of 10-24. 
48-tedenska študija, kontrolirana z aktivnim primerjalnim zdravilom Bolniki, vključeni v aktivno kontrolirano študijo, so imeli začetni rezultat MMSE ob izhodišču med 10 in 24.
In patients with Alzheimer's disease, inhibition of AChE in CSF by oral rivastigmine was dose-dependent up to 6 mg given twice daily, the highest dose tested. 
Pri bolnikih z Alzheimerjevo boleznijo je bila stopnja inhibicije AChE v CSF s peroralnim rivastigminom odvisna od odmerka do največjega preizkušanega odmerka 6 mg, danega dvakrat na dan. Inhibicija aktivnosti butirilholinesteraze v CSF pri 14 bolnikih z Alzheimerjevo boleznijo, zdravljenih s peroralnim rivastigminom, je bila podobna kot inhibicija
The backing layer is transparent to translucent and labelled with “R5” (Rivastigmine 3M Health Care Ltd. 4.6 mg/24 h transdermal patch) or “R10” (Rivastigmine 3M Health Care Ltd. 9.5 mg/24 h transdermal patch). 
Krovna plast je prozorna do prosojna in in označena z oznako “R5” (Rivastigmin 3M Health Care Ltd. 4,6 mg/24 h transdermalni obliž) ali “R10” (Rivastigmin 3M Health Care Ltd. 9,5 mg/24 h transdermalni obliž).
In the 24-week doubleblind study, the most commonly observed symptoms (skin irritation rating scale) with rivastigmine 9.5 mg/24 h transdermal patches were very slight (21.8%), mild (12.5%) or moderate (6.5%) erythema or very slight (11.9%), mild (7.3%) or moderate (5.0%) pruritus. 
V 24-tedenski dvojno slepi študiji so bili najbolj pogosto opaženi simptomi (po lestvici ocene draženja kože) s transdermalnimi obliži z rivastigminom 9,5 mg/24 h zelo blaga (21,8%), blaga (12,5%) ali zmerna (6,5%) rdečina ali zelo blago (11,9%), blago (7,3%) ali zmerno (5,0%) srbenje.
Previous history of application site reactions suggestive of allergic contact dermatitis with rivastigmine patch (see section 4.4). 
Uporaba zdravila je kontraindicirana tudi pri bolnikih, ki imajo v anamnezi reakcije na mestu apliciranja, ki bi bile lahko znak alergijskega kontaktnega dermatitisa pri uporabi transdermalnih obližev z rivastigminom (glejte poglavje 4.4).
Always use this medicine exactly as described in this leaflet and as your doctor has told you. 
Pri uporabi tega zdravila natančno upoštevajte napotke v tem navodilu in navodila zdravnika.